Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05103358 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

A Phase 2 study of Cancer and Solid Tumor, sponsored by Aadi Bioscience.

Active
Registry status
Phase 2
Development phase
120
Enrollment target
20
Study locations

NCT05103358 is a Phase 2 study of Cancer and Solid Tumor that is active but no longer recruiting, run by Aadi Bioscience. The registered enrollment target is 120 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05103358, a Phase 2 study of Cancer and Solid Tumor, is active but no longer recruiting, sponsored by Aadi Bioscience.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
120 participants
Enrollment target
20
Study locations

Study Summary

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

Conditions Studied

Cancer Solid Tumor Neoplasms Metastatic Cancer Neoplasm Metastasis Tumors Tumor Metastasis Tumor, Solid Cancer Metastatic

Interventions

  • DRUG nab-sirolimus

Study Locations (20)

California

  • PCR Oncology - Arroyo Grande
  • Nextgen Oncology - Beverly Hills
  • City of Hope - Duarte
  • Providence Medical Foundation (Fullerton) - Fullerton
  • MemorialCare - Long Beach
  • USC Norris Comprehensive Cancer Center - Los Angeles
  • UCLA - Jonsson Comprehensive Cancer Center - Los Angeles
  • Providence Medical Foundation (Napa) - Napa
  • Hoag Memorial Hospital Presbyterian - Newport Beach
  • Sharp HealthCare - San Diego
  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
  • Ridley-Tree Cancer Center - Santa Barbara
  • Sarcoma Oncology Research Center - Santa Monica
  • Providence Medical Foundation - Santa Rosa

Arizona

  • Arizona Oncology Associates - Goodyear
  • Honor Health - Phoenix
  • Arizona Oncology Associates - Prescott Valley
  • Yuma Regional Medical Center - Yuma

Alabama

  • Alabama Oncology - Birmingham
  • Southern Cancer Center - Mobile

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2022-02-15
Est. Completion 2025-12-31
Phase Phase 2

Sponsor

Aadi Bioscience

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05103358

The ClinicalTrials.gov registry entry for NCT05103358 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Aadi Bioscience, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which nab-sirolimus is the first listed.

NCT05103358 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.

Frequently Asked Questions

What is clinical trial NCT05103358 about?

NCT05103358 is a clinical study titled "Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)". A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

What is the current status of trial NCT05103358?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2022-02-15. Estimated completion is 2025-12-31.

What conditions does trial NCT05103358 study?

This clinical trial studies the following conditions: Cancer, Solid Tumor, Neoplasms, Metastatic Cancer, Neoplasm Metastasis.

What interventions are being tested in trial NCT05103358?

The interventions under investigation include: nab-sirolimus (DRUG).

Who is sponsoring clinical trial NCT05103358?

This trial is sponsored by Aadi Bioscience, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05103358 being conducted?

This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Solid Tumor

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.